Patients receiving avacopan treatment exhibited significant differences in cumulative incidence across different age groups (log-rank test, p < 0.00012), and those who developed hepatobiliary disorders also showed significant differences in cumulative incidence of AEs compared to other SOC levels (log-rank test, p < 0.0001). The gene discussed is UBXN11; the disease is hepatobiliary disorder.